Information Provided By: 
Fly News Breaks for December 19, 2019
MGNX
Dec 19, 2019 | 06:47 EDT
Cantor Fitzgerald analyst Varun Kumar last night initiated coverage of MacroGenics with an Overweight rating and $17 price target. The shares have recently traded based on prospects for the company's lead asset margetuximab in HER2+ breast cancer, Kumar tells investors in a research note. However, he believes the narrative "needs to now change" as the market appears to underappreciate a "partially de-risked" asset in flotetuzumab and MacroGenics' "attractive pipeline optionality."
News For MGNX From the Last 2 Days
MGNX
Apr 26, 2024 | 10:06 EDT
MGNX
Apr 26, 2024 | 07:26 EDT
B. Riley initiated coverage of MacroGenics with a Buy rating and $25 price target. The analyst views the company's most advanced candidate, vobra duo, as "significantly de-risked" in the ongoing over-enrolled Phase II TAMARACK registration-enabling study, the analyst tells investors in a research note. The firm MacroGenics' fully integrated development and manufacturing capabilities have led to a partnered program portfolio consisting of three FDA-approved medicines and earlier-stage pipeline candidates.
MGNX
Apr 26, 2024 | 07:09 EDT
B. Riley initiated coverage of MacroGenics with a Buy rating and $25 price target.
